7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Thirunavukkarasu K et al. | Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. | 2001 | J. Biol. Chem. | pmid:11451955 |
| Choi Y et al. | Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. | 2001 | Eur. J. Immunol. | pmid:11449372 |
| Sakiyama H et al. | Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. | 2001 | J. Bone Miner. Metab. | pmid:11448014 |
| Szulc P et al. | Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11443182 |
| Haynes DR et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. | 2001 | Rheumatology (Oxford) | pmid:11426018 |
| Kim KJ et al. | Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. | 2001 | J. Biomed. Mater. Res. | pmid:11410897 |
| Fazzalari NL et al. | The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. | 2001 | J. Bone Miner. Res. | pmid:11393778 |
| Kon T et al. | Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. | 2001 | J. Bone Miner. Res. | pmid:11393777 |
| Abu-Amer Y | IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. | 2001 | J. Clin. Invest. | pmid:11390419 |
| Morony S et al. | Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. | 2001 | Cancer Res. | pmid:11389072 |
| Hein GE | [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. | 2001 | Z Rheumatol | pmid:11383046 |
| Kanzaki H et al. | Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. | 2001 | J. Dent. Res. | pmid:11379890 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Luger NM et al. | Osteoprotegerin diminishes advanced bone cancer pain. | 2001 | Cancer Res. | pmid:11358823 |
| Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
| Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |
| Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
| Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
| Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
| Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
| Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
| Hofbauer LC et al. | Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. | 2001 | J. Rheumatol. | pmid:11327234 |
| Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
| Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
| Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
| Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
| Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
| Collin-Osdoby P et al. | Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. | 2001 | J. Biol. Chem. | pmid:11274143 |
| Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
| Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
| Wada N et al. | Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. | 2001 | J. Periodont. Res. | pmid:11246705 |
| Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
| Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
| Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
| Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
| Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
| Hofbauer LC and Heufelder AE | [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. | 2001 | Dtsch. Med. Wochenschr. | pmid:11233883 |
| Leach RJ et al. | The genetics of Paget's disease of the bone. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11231972 |
| Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
| Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
| Kikuchi T et al. | Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. | 2001 | J. Immunol. | pmid:11207318 |
| Bekker PJ et al. | The effect of a single dose of osteoprotegerin in postmenopausal women. | 2001 | J. Bone Miner. Res. | pmid:11204435 |
| Wise GE et al. | Osteoprotegerin and osteoclast differentiation factor in tooth eruption. | 2000 | J. Dent. Res. | pmid:11201042 |
| Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Osteoporos Int | pmid:11193242 |
| Clohisy DR et al. | Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | 2000 | J. Orthop. Res. | pmid:11192258 |
| Bénard J | [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? | 2000 | Bull Cancer | pmid:11184451 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Makiishi-Shimobayashi C et al. | Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11181055 |